<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940391</url>
  </required_header>
  <id_info>
    <org_study_id>H-1093-054-1017</org_study_id>
    <nct_id>NCT03940391</nct_id>
  </id_info>
  <brief_title>Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy</brief_title>
  <official_title>Effect of an Adjunctive Sedative for the Patients With Histories of Paradoxical Reaction to Midazolam During Sedative Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-blind prospective study is aimed to investigate the effect of antihistamine as an&#xD;
      adjunctive sedative for the patients with histories of severe paradoxical reaction to&#xD;
      midazolam during sedative endoscopy. Participating patients are to receive antihistamine&#xD;
      intravenously in addition to midazolam. The primary outcome is the reduction of paradoxical&#xD;
      reaction in the antihistamine combination group. The secondary outcome is to compare sedation&#xD;
      quality, performance quality, reduction of total midazolam dose will be analyzed between&#xD;
      antihistamine combination and midazolam only group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study will be conducted at Seoul National University Hospital Gangnam center&#xD;
      between May 2019 and April 2020. Participants who have histories of paradoxical reaction to&#xD;
      sedative endoscopy in medical record gave consent on the day of the endoscopy and were&#xD;
      assigned to receive the combination of chlorpheniramine (4-6mg) with midazolam(1-10mg)&#xD;
      Meanwhile, the patients do not want the use of chlorpheniramine and were assigned to&#xD;
      midazolam alone as routine clinical practice. Research medication (chlorpheniramine) was&#xD;
      administered 2 to 3 minutes before the administration of midazolam outside of endoscopy room.&#xD;
      The blinded endoscopist and assistant nurse are going to perform induction for moderate&#xD;
      sedation using incremental doses of the intravenous midazolam (1-2 mg) given every 2 minutes.&#xD;
      The endoscopists and assistant nurses will assess the occurrence of severe paradoxical&#xD;
      reaction (Grade 3) and other major quality outcomes (procedure/intubation time, sedation&#xD;
      quality, completeness of procedure [10 Key image documentation], the satisfaction of&#xD;
      procedure, side effects). The endoscopists and nurses will individually rate outcome measure&#xD;
      using a 5-point Likert scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of severe paradoxical reaction (&gt;= level 3)</measure>
    <time_frame>1 day</time_frame>
    <description>(1) irrational talking or increased talkativeness such as mumbling to himself/herself; (2) restlessness or loss of cooperation such as resisting the insertion of endoscope or trying to bite the scope; (3) excessive movement requiring repositioning such as jerking or swinging movements of the arms and legs or trying to draw out the scope or mouthpiece; and (4) hostile action such as trying to strike the endoscopists or attending nurses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>procedure/intubation time</measure>
    <time_frame>1 day</time_frame>
    <description>procedural time (time from scope insertion to scope out) Intubation time (time from scope insertion to upper esophagus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of midazolam</measure>
    <time_frame>1 day</time_frame>
    <description>total amount of benzodiazepine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>completeness of procedure</measure>
    <time_frame>1 day</time_frame>
    <description>photo documentation of key anatomical area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction for Quality of sedation</measure>
    <time_frame>1 day</time_frame>
    <description>5-point Likert scale : endoscopists and assistant nurses&#xD;
Strongly unsatisfied&#xD;
Unsatisfied&#xD;
Neither satisfied nor unsatisfied&#xD;
Satisfied&#xD;
Strongly satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction for the procedure</measure>
    <time_frame>1 day</time_frame>
    <description>5-point Likert scale for pain and sedation: patients&#xD;
Strongly unsatisfied&#xD;
Unsatisfied&#xD;
Neither satisfied nor unsatisfied&#xD;
Satisfied&#xD;
Strongly satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1 day</time_frame>
    <description>hypoxia, arrythmia, low blood pressure and administration of antidote</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>antihistamine combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will get combination chlorpheniramine and midazolam injection for sedative endoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will get only midazolam injection for sedative endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorpheniramine and midazolam</intervention_name>
    <description>Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.</description>
    <arm_group_label>antihistamine combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.</description>
    <arm_group_label>midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous histories of the paradoxical reaction during a sedative endoscopic&#xD;
             examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to execute informed consent&#xD;
&#xD;
          -  allergic to antihistamine agent&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  severe cardiopulmonary disease&#xD;
&#xD;
          -  prior administration of antihistamine on the same day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Healthcare System Gangnam Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Sachar H, Pichetshote N, Nandigam K, Vaidya K, Laine L. Continued midazolam versus diphenhydramine in difficult-to-sedate patients: a randomized double-blind trial. Gastrointest Endosc. 2018 May;87(5):1297-1303. doi: 10.1016/j.gie.2017.01.028. Epub 2017 Jan 31.</citation>
    <PMID>28159539</PMID>
  </results_reference>
  <results_reference>
    <citation>Nusrat S, Madhoun MF, Tierney WM. Use of diphenhydramine as an adjunctive sedative for colonoscopy in patients on chronic opioid therapy: a randomized controlled trial. Gastrointest Endosc. 2018 Oct;88(4):695-702. doi: 10.1016/j.gie.2018.04.2342. Epub 2018 Apr 22.</citation>
    <PMID>29689257</PMID>
  </results_reference>
  <results_reference>
    <citation>Tae CH, Kang KJ, Min BH, Ahn JH, Kim S, Lee JH, Rhee PL, Kim JJ. Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil. Dig Liver Dis. 2014 Aug;46(8):710-5. doi: 10.1016/j.dld.2014.04.007. Epub 2014 Jun 2.</citation>
    <PMID>24893689</PMID>
  </results_reference>
  <results_reference>
    <citation>Tu RH, Grewall P, Leung JW, Suryaprasad AG, Sheykhzadeh PI, Doan C, Garcia JC, Zhang N, Prindiville T, Mann S, Trudeau W. Diphenhydramine as an adjunct to sedation for colonoscopy: a double-blind randomized, placebo-controlled study. Gastrointest Endosc. 2006 Jan;63(1):87-94.</citation>
    <PMID>16377322</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Su Jin Chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>paradoxical reaction</keyword>
  <keyword>midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpheniramine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

